An observational study in Myocardial Ischemia, Acute Coronary Syndrome and Myocardial Infarction, sponsored by University of Zurich. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2012-05-31.
Sponsored by University of Zurich · Observational
The purpose of the study is the evaluation of multiple biomarkers related to acute coronary syndromes, including myeloid-related protein 8/14 (MRP 8/14), along with established clinical markers, for early diagnosis and risk stratification in patients presenting with acute chest pain at the emergency department.
Study hypothesis: MRP 8/14, alone or together with other established or new biomarkers, increases the earliness, sensitivity, and specificity of diagnosing acute coronary syndromes.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 403 is below the median of 500 across 983 observational studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →University of Zurich is the lead sponsor of 1,030 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients - systematic sampling - presenting with acute chest pain at the emergency room in which determination of cardiac biomarkers is indicated for clinical diagnostics
Exclusion Criteria:
Diagnosis of acute coronary syndrome
Time frame: Emergency room and/or hospital stay
Incidence of any acute coronary event
Time frame: 1 year
Morbidity from coronary artery disease
Time frame: 1 year
Mortality
Time frame: 1 year
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Zurich